|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
Tumor necrosis factor (ligand) superfamily, member 8 Protein Datasheet
CD30 Ligand / TNFSF8 Protein Price Inquiry ( Available Sizes )
CD30 Ligand / TNFSF8 Protein Product Information
A DNA sequence encoding the ratTNFSF8(Gln66-Asp237) was expressed with Fc region of human IgG1 at the N-terminus.
|Expression Host:||Human Cells|
CD30 Ligand / TNFSF8 Protein QC Testing
|Purity:||> 90 % as determined by SDS-PAGE||SDS-PAGE:
CD30 Ligand / TNFSF8 protein
|Endotoxin:||< 1.0 EU per μg of the protein as determined by the LAL method|
|Stability:||Samples are stable for up to twelve months from date of receipt at -70℃|
|Predicted N terminal:||Glu|
The recombinant rat TNFSF8 comprises 432 amino acids and predicts a molecular mass of 47.9 kDa. The apparent molecular mass of the recombinant protein is approximately 58 kDa in SDS-PAGE under reducing conditions due to glycosylation.
|Formulation:||Lyophilized from sterile PBS, pH 7.4.
CD30 Ligand / TNFSF8 Protein Usage Guide
|Storage:||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|Reconstitution:||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.|
CD30 Ligand / TNFSF8 Protein Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|CD153/CD30L/TNFSF8||Human||CD153/CD30L/TNFSF8/Fc Protien, Recombinant||10040-H01H|
|CD153/CD30L/TNFSF8||Rat||CD30 Ligand / TNFSF8 Protein, Recombinant||80148-R01H|
CD30 Ligand / TNFSF8 Protein Description
CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a cytokine belonging to the emerging tumor necrosis factor (TNF) ligand superfamily, and is a specific ligand for CD30/ TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response.
- Gruss HJ. et al.,1994, Blood. 83: 2045-56.
- Croager EJ. et al., 1997, Biochim Biophys Acta 1353: 231-5.
- Wendtner CM. et al., 1995, Cancer Res. 55: 4157-61.
- Fischer M. et al., 2006, J Clin Invest. 116: 2748-56.
- Blazar BR. et al., 2004, J Immunol. 173: 2933-41.